Now showing items 1-1 of 1

    • Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). 

      Welti, J; Sharp, A; Yuan, W; Dolling, D; Nava Rodrigues, D; Figueiredo, I; Gil, V; Neeb, A; Clarke, M; Seed, G; Crespo, M; Sumanasuriya, S; Ning, J; Knight, E; Francis, JC; Hughes, A; Halsey, WS; Paschalis, A; Mani, RS; Raj, GV; Plymate, SR; Carreira, S; Boysen, G; Chinnaiyan, AM; Swain, A; de Bono, JS; International SU2C/PCF Prostate Cancer Dream Team (2018-07)
      <b>Purpose:</b> Persistent androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC) and confers resistance to AR-targeting therapies. Novel therapeutic strategies to overcome this are urgently ...